Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims Stand Finally Rejected
- Anti-Patent Strategy Leads to Lykos’ Late Filing, Focus on the “Particle Size” of its MDMA
- To What End?
- Strength of the Patent
- Particle Sizes
- Salts & Solvates
- New Examinations, New Dilemmas
- First Office Action
- ‘Final’ Office Action
- What’s Next?
- What Value Remains?
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In